Literature DB >> 11913504

Serological and molecular evidence of human granulocytic ehrlichiosis focus in the Białowieza Primeval Forest (Puszcza Białowieska), northeastern Poland.

A Grzeszczuk1, J Stańczak, B Kubica-Biernat.   

Abstract

Human granulocytic ehrlichiosis (HGE) is an emerging tickborne zoonosis. First described in the USA, it is being increasingly reported from several European countries. This study was undertaken to provide serological and molecular evidence of the occurrence of the HGE focus in the Białowieza Primeval Forest, located in northeastern Poland. To this end, the seroprevalence of HGE in this area, where Lyme borreliosis and tickborne encephalitis are highly endemic, was determined by means of an indirect immunofluorescence antibody assay. In addition, the frequency of granulocytic Ehrlichia spp. infection in Ixodes ricinus ticks from the same area was estimated using a polymerase chain reaction method with EHR 521 and EHR 747 primers, which amplified a fragment of 16S rDNA. The rate of seropositivity for HGE was 6.2% (8/130 subjects). Individuals seropositive for Lyme borreliosis were more likely to have anti-HGE antibodies than seronegative ones (P<0.05; OR=6.34, 95%CI=1.12-36.98). There was no association between self-reported frequency of tick bites or forestry employment and HGE seropositivity. Sixty of 376 (16%) Ixodes ricinus ticks tested were positive for the Ehrlichia phagocytophila genogroup by polymerase chain reaction. Ehrlichial DNA was present in 59 of 302 (19.5%) adult ticks and in 1 of 74 nymphs (1.4%). There was a significantly higher infection rate among female ticks (32.9%; 49/149) than among male ticks (6.5%; 10/153) (P<0.05). Dual infection with Ehrlichia spp. and Borrelia burgdorferi sensu lato was detected in 10 samples that were positive for ehrlichiae. The results obtained confirm the perpetuation of the HGE agent in the primeval forest ecosystem of northeastern Poland.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11913504     DOI: 10.1007/s10096-001-0649-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Detection of Anaplasma phagocytophilum in Amblyomma flavomaculatum ticks (Acari: Ixodidae) collected from lizard Varanus exanthematicus imported to Poland.

Authors:  Magdalena Nowak; Stella Cieniuch; Joanna Stańczak; Krzysztof Siuda
Journal:  Exp Appl Acarol       Date:  2010-01-19       Impact factor: 2.132

2.  High diversity of ankA sequences of Anaplasma phagocytophilum among Ixodes ricinus ticks in Germany.

Authors:  Friederike D von Loewenich; Birgit U Baumgarten; Klaus Schröppel; Walter Geissdörfer; Martin Röllinghoff; Christian Bogdan
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

3.  Distribution of Dermacentor silvarum and Associated Pathogens: Meta-Analysis of Global Published Data and a Field Survey in China.

Authors:  Wen-Bin Guo; Wen-Qiang Shi; Qian Wang; Yu-Sheng Pan; Qiao-Cheng Chang; Bao-Gui Jiang; Jing-Xia Cheng; Xiao-Ming Cui; Yu-Hao Zhou; Jia-Te Wei; Yi Sun; Jia-Fu Jiang; Na Jia; Wu-Chun Cao
Journal:  Int J Environ Res Public Health       Date:  2021-04-22       Impact factor: 3.390

4.  Molecular characterization of a defensin gene from a hard tick, Dermacentor silvarum.

Authors:  Juanjuan Wang; Gang Bian; Wen Pan; Tingting Feng; Jianfeng Dai
Journal:  Parasit Vectors       Date:  2015-01-15       Impact factor: 3.876

5.  Human Exposure to Anaplasma phagocytophilum in Two Cities of Northwestern Morocco.

Authors:  Sarah Elhamiani Khatat; Hamid Sahibi; Mony Hing; Ismail Alaoui Moustain; Hamid El Amri; Mohammed Benajiba; Malika Kachani; Luc Duchateau; Sylvie Daminet
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

6.  Prevalence of serological response to Borrelia burgdorferi in farmers from eastern and central Poland.

Authors:  V Zając; J Pinkas; A Wójcik-Fatla; J Dutkiewicz; A Owoc; I Bojar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-31       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.